CorpusAnalytiX and Ariana Pharma Announce Collaborative Alliance to Accelerate AI-Driven Drug Development

One unique aspect of CorpusAnalytiX is its supplier-centric model, which empowers data generators—such as biotech startups and research labs—to maintain control over their datasets while monetizing them effectively. Unlike other platforms that aggregate and sell datasets directly, CorpusAnalytiX operates on a model that allows suppliers to set their own prices, ensuring equitable compensation and enabling suppliers to leverage their previously underutilized datasets.

CorpusAnalytiX's B2B marketplace simplifies the healthcare data acquisition process by linking biotech SMEs, university labs, and pharmaceutical companies with a network of US and EU data suppliers. The platform's practical e-commerce interface allows prospective buyers to specify metadata and annotation requirements through custom queries, ensuring precise matching of research needs with available data. Buyers benefit from faster access to various datasets while suppliers manage their assets, choosing flexible licensing options and empowering them to become contract research organizations.

Through this partnership, Ariana Pharma will be able to tap into CorpusAnalytiX's expanding repository, including:

• →Whole-exome sequencing data from over 20,000 genes
• →More than 10 million pathology whole slide images
• →2 million+ HIPAA-compliant, de-identified electronic health records
• →Care pathways, simulations, multi-omics data, failed clinical trial information, and other niche datasets

Ariana Pharma's KEM® eXplainable AI platform integrates extensive pre-clinical, clinical, and real-world evidence data to de-risk clinical development by improving clinical trial design and execution. By incorporating CorpusAnalytiX's vast ecosystem, Ariana Pharma aims to:

• →Refine patient stratification and biomarker identification
• →Propose innovative, precision medicine biomarker-based clinical study designs
• →Fast-track drug repurposing and indication expansion efforts
• →Bolster real-world evidence generation to support regulatory submissions

The collaboration will initially focus on oncology and rare diseases but will expand into other therapeutic areas as the partnership progresses. "By facilitating access to previously siloed datasets, we're working to provide Ariana Pharma with a more varied pool of information," explained Tandon. "We believe this collaboration has the potential to contribute to reducing the time and cost associated with bringing new therapies to market." Parmentier added, "The breadth and depth of data available through the CorpusAnalytiX platform could allow us to develop more robust xAI algorithms, potentially leading to more accurate predictions and better-designed clinical trials."

CorpusAnalytiX is a B2B healthcare data brokerage that connects biotech SMEs, laboratories, researchers, and pharmaceutical companies with novel datasets from diverse sources such as pathology firms, D2C genetic testing startups, and concierge clinics. By streamlining data acquisition and unlocking access to unique datasets, CorpusAnalytiX's one-stop-shop platform accelerates healthcare innovation. Unlock groundbreaking biomedical insights at www.corpusanalytix.com.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.